Referencias bibliográficas

1. Zalc B. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain. 2018 Dec 1;141(12):3482-8. [Pubmed]
2. Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest. 1942 Sep;21(5):571-7. [Pubmed]
3. Frick E, Scheid-Seydel L. [Research with I 131-labelled gamma-globupin on the problem of the origin of cerebrospinal fluid proteins]. Klin Wochenschr. 1960 Dec 15;38:1240-3. German. [Pubmed]
4. Lowenthal A, Vansande M, Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem. 1960 Aug;6:51-6. [Pubmed]
5. Karcher D, Van Sande M, Lowenthal A. Micro-electrophoresis in agar gel of proteins of the cerebrospinal fluid and central nervous system. J Neurochem. 1959 Jun;4(2):135-40. [Pubmed]
6. Laterre EC. [Agar gel electrophoresis of cerebrospinal fluid proteins. Semiology of the gamma zone]. Acta Neurol Psychiatr Belg. 1966 Apr;66(4):289-304. French. [Pubmed]
7. Laterre EC, Callewaert A, Heremans JF, Sfaello Z. Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system. Neurology. 1970 Oct;20(10):982-90. [Pubmed]
8. Holmøy T. The discovery of oligoclonal bands: a 50-year anniversary. Eur Neurol. 2009;62(5):311-5. [Pubmed]
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227-31. [Pubmed]
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. [Pubmed]
11. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 Dec;58(6):840-6. [Pubmed]
12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. [Pubmed]
13. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. [Pubmed]
14. Pérez-Miralles FC, Alcalá Vicente C, Boscá Blasco I. Diagnóstico de las enfermedades desmielinizantes con afectación opticoespinal. En: Monografías en esclerosis múltiple XIV: enfermedades desmielinizantes con afectación óptica y medular en la esclerosis múltiple. Grupo Acción Médica; 2014. Disponible en: [Enlace]
15. Kölliker Frers RA, Otero-Losada M, Kobiec T, Udovin LD, Aon Bertolino ML, Herrera MI, Capani F. Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis. Front Immunol. 2022 Jul 28;13:912005. [Pubmed]
16. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347-66. [Pubmed]
17. Rolan P, Atkinson AJ Jr, Lesko LJ; Scientific Organizing Committee; Conference Report Committee. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther. 2003 Apr;73(4):284-91. [Pubmed]
18. Moral Torres, E, Mendibe Bilbao M, Oreja Guevara C, Fernández Fernández O, Montalbán Gairin X, Rodríguez Antigüedad A. Guía oficial de práctica clínica en esclerosis múltiple. Sociedad Española de Neurología; 2014. Disponible en: [Enlace]
19. Andlovic A, Babič M, Accetto S, Rot U. Comparison of two methods for the detection of oligoclonal bands in a large number of clinically isolated syndrome and multiple sclerosis patients. Clin Neurol Neurosurg. 2012 Jul;114(6):659-62. [Pubmed]
20. Álvarez-Cermeño JC, Villar LM. Multiple sclerosis: Oligoclonal bands--a useful tool to avoid MS misdiagnosis. Nat Rev Neurol. 2013 Jun;9(6):303-4. [Pubmed]
21. Masjuán J, Álvarez-Cermeño JC, García-Barragán N, Díaz-Sánchez M, Espiño M, Sádaba MC, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006 Feb 28;66(4):576-8. [Pubmed]
22. Tintoré M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. [Pubmed]
23. Dorta-Contreras AJ. [Reibergrams: essential element in cerebrospinal fluid immunological analysis]. Rev Neurol. 1999 May 16-31;28(10):996-8. Spanish. [Pubmed]
24. Blennow K, Fredman P, Wallin A, Gottfries CG, Frey H, Pirttilä T, et al. Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis. J Neurol Sci. 1994 Jan;121(1):90-6. [Pubmed]
25. Sanz Diaz CT, de Las Heras Flórez S, Carretero Perez M, Hernández Pérez MÁ, Martín García V. Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure. Front Neurol. 2021 Aug 11;12:676527. [Pubmed]
26. Gaetani L, Di Carlo M, Brachelente G, Valletta F, Eusebi P, Mancini A, et al. Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. J Neuroimmunol. 2020 Feb 15;339:577108. [Pubmed]
27. Hegen H, Arrambide G, Gnanapavan S, Kaplan B, Khalil M, Saadeh R, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Mult Scler. 2023 Feb;29(2):182-95. [Pubmed]
28. Adamec I, Bošković M, Škvorc A, Posavec V, Radmilović M, Gabelić T, Habek M. Do we need broad immunological work-up in all patients with CIS? J Neurol Sci. 2012 Apr 15;315(1-2):86-8. [Pubmed]
29. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, Podemski R, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012 Apr;21(4):412-20. [Pubmed]
30. Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, et al. Should we systematically test patients with clinically isolated syndrome for auto-antibodies? Mult Scler. 2015 Dec;21(14):1802-10. [Pubmed]
31. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. [Pubmed]
32. Ho JD, Yeh R, Sandstrom A, Chorny I, Harries WE, Robbins RA, et al. Crystal structure of human aquaporin 4 at 1.8 A and its mechanism of conductance. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7437-42. [Pubmed]
33. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008 Apr;4(4):202-14. [Pubmed]
34. Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014 Oct;5(3):290-303. [Pubmed]
35. Kowarik MC, Dzieciatkowska M, Wemlinger S, Ritchie AM, Hemmer B, Owens GP, Bennett JL. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation. 2015 Jan 28;12:19. [Pubmed]
36. Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e231. [Pubmed]
37. Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022 Jun 17;13:885218. [Pubmed]
38. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003 Jul 10;349(2):139-45. [Pubmed]
39. Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):739-42. [Pubmed]
40. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007 Jan 25;356(4):371-8. [Pubmed]
41. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology. 2004 Jun 8;62(11):2092-4. [Pubmed]
42. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007 Feb;13(2):211-7. [Pubmed]
43. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. [Pubmed]
44. Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163. [Pubmed]
45. Redenbaugh V, Montalvo M, Sechi E, Buciuc M, Fryer JP, McKeon A, et al. Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2021 Nov 26;7(4):20552173211052656. [Pubmed]
46. Carnero Contentti E, López PA, Pettinicchi JP, Pappolla A, Míguez J, Patrucco L, et al. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Mult Scler Relat Disord. 2021 Apr;49:102742. [Pubmed]
47. Spiezia AL, Carotenuto A, Iovino A, Moccia M, Gastaldi M, Iodice R, et al. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature. Int J Mol Sci. 2022 Nov 23;23(23):14559. [Pubmed]
48. Macrini C, Gerhards R, Winklmeier S, Bergmann L, Mader S, Spadaro M, et al. Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain. 2021 Sep 4;144(8):2375-89. [Pubmed]
49. Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G, et al. Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. 2020 Dec;267(12):3555-64. [Pubmed]
50. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 3;15(1):134. [Pubmed]
51. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019 May;266(5):1280-6. [Pubmed]
52. Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):e674. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020 Mar 20;7(3): [Pubmed]
53. Mariotto S, Gajofatto A, Batzu L, Delogu R, Sechi G, Leoni S, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. 2019 Nov 12;93(20):e1867-e1872. [Pubmed]
54. Kwon YN, Kim B, Kim JS, Mo H, Choi K, Oh SI, et al. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 28;9(1):e1095. [Pubmed]
55. Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021 Jul 6;97(1):e1-e12. [Pubmed]
56. Dalmau J, Dalakas MC, Kolson DL, Paul F, Sánchez-Valle R, Zamvil SS. N2 Year in Review. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 3;10(1):e200076. [Pubmed]
57. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Jan 24:S1474-4422(22)00431-8. Epub ahead of print. [Pubmed]
58. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001 Nov;50(5):646-57. [Pubmed]
59. Dintzis HM, Dintzis RZ. Profound specific suppression by antigen of persistent IgM, IgG, and IgE antibody production. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1113-7. [Pubmed]
60. Villar LM, Sádaba MC, Roldán E, Masjuán J, González-Porqué P, Villarrubia N, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest. 2005 Jan;115(1):187-94. [Pubmed]
61. Beltrán E, Hernández A, Lafuente EM, Coret F, Simó-Castelló M, Boscá I, et al. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis. J Neuroimmunol. 2012 Jun 15;247(1-2):63-9. [Pubmed]
62. Beltrán E, Obermeier B, Moser M, Coret F, Simó-Castelló M, Boscá I, et al. Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain. 2014 Oct;137(Pt 10):2703-14. [Pubmed]
63. Espiño M, Abraira V, Arroyo R, Bau L, Cámara C, Campos-Ruiz L, et al. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin Chim Acta. 2015 Jan 1;438:67-9. [Pubmed]
64. Villar LM, Masjuán J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002 Aug 27;59(4):555-9. [Pubmed]
65. Ozakbas S, Cinar BP, Özcelik P, Baser H, Kosehasanoğullari G. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results. Clin Neurol Neurosurg. 2017 Sep;160:27-9. [Pubmed]
66. Magraner MJ, Bosca I, Simó-Castelló M, García-Martí G, Alberich-Bayarri A, Coret F, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012 Jan;54(1):5-12. [Pubmed]
67. Bosca I, Villar LM, Coret F, Magraner MJ, Simó-Castelló M, Álvarez-Cermeño JC, Casanova B. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult Scler. 2010 Jul;16(7):810-5. [Pubmed]
68. Casanova B, Lacruz L, Villar ML, Domínguez JA, Gadea MC, Gascón F, et al. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients. Neurol Sci. 2018 Aug;39(8):1423-30. [Pubmed]
69. Alcalá Vicente C, Lacruz L, Gascón F, Carratalà S, Quintanilla-Bordás C, Sanz MT, et al. Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. Front Neurol. 2022 Oct 28;13:991596. [Pubmed]
70. Coll-Martínez C, Quintana E, Buxó M, Salavedra-Pont J, Gasull-Vicens L, Quiroga-Varela A, et al. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis. Mult Scler Relat Disord. 2022 Dec;68:104397. [Pubmed]
71. Villar LM, Costa-Frossard L, Masterman T, Fernández O, Montalbán X, Casanova B, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol. 2015 Mar;77(3):447-57. [Pubmed]
72. Toboso I, Tejeda-Velarde A, Álvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, et al. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Front Neurol. 2020 Dec 17;11:579438. [Pubmed]
73. Villar LM, Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol. 2014 Aug;76(2):231-40. [Pubmed]
74. Casanova B, Castillo J, Quintanilla-Bordás C, Sanz MT, Fernández-Velasco JI, Alcalá C, et al. Oligoclonal M bands unveil occult inflammation in multiple sclerosis. Mult Scler Relat Disord. 2022 Dec;68:104118. [Pubmed]
75. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-81. [Pubmed]
76. Nötzel M, Werder LI, Ziemssen T, Akgün K. Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients. Int J Mol Sci. 2022 Oct 15;23(20):12361. [Pubmed]
77. Lee S, Plavina T, Singh CM, Xiong K, Qiu X, Rudick RA, et al. Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform. Front Neurol. 2022 Jul 25;13:935382. [Pubmed]
78. Lambertsen KL, Soares CB, Gaist D, Nielsen HH. Neurofilaments: The C-Reactive Protein of Neurology. Brain Sci. 2020 Jan 18;10(1):56. [Pubmed]
79. Ferreira-Atuesta C, Reyes S, Giovanonni G, Gnanapavan S. The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Front Neurosci. 2021 Apr 6;15:642384. [Pubmed]
80. Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol. 2019 Nov 1;76(11):1359-66. [Pubmed]
81. Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017 Nov 28;89(22):2230-7. [Pubmed]
82. Preziosa P, Rocca MA, Filippi M. Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. Expert Rev Neurother. 2020 Aug;20(8):747-69. [Pubmed]
83. Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ. Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis. Mult Scler. 2020 May;26(6):659-67. [Pubmed]
84. Uher T, Schaedelin S, Srpova B, Barro C, Bergsland N, Dwyer M, et al. Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurol Neuroimmunol Neuroinflamm. 2020 Apr 9;7(4):e714. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020 Nov 25;8(1): [Pubmed]
85. Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, et al. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 Mar;59:103535. [Pubmed]
86. Fitzgerald KC, Sotirchos ES, Smith MD, Lord HN, DuVal A, Mowry EM, Calabresi PA. Contributors to Serum NfL Levels in People without Neurologic Disease. Ann Neurol. 2022 Oct;92(4):688-98. [Pubmed]
87. Bridel C, Verberk IMW, Heijst JJA, Killestein J, Teunissen CE. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. Mult Scler Relat Disord. 2021 Jan;47:102666. [Pubmed]
88. Alcalá C, Cubas L, Carratalá S, Gascón F, Quintanilla-Bordás C, Gil-Perotín S, et al. NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity. J Neurol. 2022 Jul;269(7):3495-500. [Pubmed]
89. Yik JT, Becquart P, Gill J, Petkau J, Traboulsee A, Carruthers R, et al. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis. Mult Scler Relat Disord. 2022 Jan;57:103366. [Pubmed]
90. Martin SJ, McGlasson S, Hunt D, Overell J. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059-67. [Pubmed]
91. Pérez-Miralles F, Prefasi D, García-Merino A, Gascón-Giménez F, Medrano N, Castillo-Villalba J, et al. CSF chitinase 3-like-1 association with disability of primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 1;7(5):e815. [Pubmed]
92. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, et al.; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022 Mar;21(3):246-57. [Pubmed]
93. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006 May;53(2):172-209. [Pubmed]
94. Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmeström C. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol. 2016 Mar 15;292:52-7. [Pubmed]
95. Tizaoui K, Yang JW, Lee KH, Kim JH, Kim M, Yoon S, et al. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. Int J Biol Sci. 2022 May 21;18(9):3731-46. [Pubmed]
96. Chavan V, Sabavath S, Babu CH, Boyapati L. Estimation of YKL-40 Acute-Phase Protein in Serum of Patients with Periodontal Disease and Healthy Individuals: A Clinical-Biochemical Study. Contemp Clin Dent. 2019 Apr-Jun;10(2):249-55. [Pubmed]
97. Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I, Price PA. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999 Dec;42(12):2624-30. [Pubmed]
98. Hall F. YKL-40 (HCgp-39) in giant cell arteritis. Arthritis Res Ther. 2000;2:66778. Disponible en: [Enlace]
99. Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights. 2007 May 3;2:128-46. [Pubmed]
100. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2000 Jul;59(7):544-8. [Pubmed]
101. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012 Jul;22(4):530-46. [Pubmed]
102. Cubas-Núñez L, Gil-Perotín S, Castillo-Villalba J, López V, Solís Tarazona L, Gasqué-Rubio R, et al. Potential Role of CHI3L1+ Astrocytes in Progression in MS. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 3;8(3):e972. [Pubmed]
103. Comabella M, Fernández M, Martín R, Rivera-Vallvé S, Borrás E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 Apr;133(Pt 4):1082-93. [Pubmed]
104. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015 Apr;138(Pt 4):918-31. [Pubmed]
105. Cantó E, Reverter F, Morcillo-Suárez C, Matesanz F, Fernández O, Izquierdo G, et al. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler. 2012 Jul;18(7):983-90. [Pubmed]
106. Gil-Perotin S, Castillo-Villalba J, Cubas-Núñez L, Gasque R, Hervas D, Gómez-Mateu J, et al. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol. 2019 Sep 23;10:1008. [Pubmed]
107. Floro S, Carandini T, Pietroboni AM, De Riz MA, Scarpini E, Galimberti D. Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2022 May 9;9(4):e1164. [Pubmed]
108. Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-García L, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023 Feb 6. Epub ahead of print. [Pubmed]
109. Londoño AC, Mora CA. Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis. F1000Res. 2018 Apr 27;7:514. [Pubmed]
110. Pachner A. The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. Biomedicines. 2022 Aug 28;10(9):2099. [Pubmed]
111. Lucchini M, De Arcangelis V, Piro G, Nociti V, Bianco A, De Fino C, et al. CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis. Mol Neurobiol. 2023 Jan;60(1):36-50. [Pubmed]
112. Mansoor SR, Ghasemi-Kasman M, Yavarpour-Bali H. The role of microRNAs in multiple sclerosis. Int Rev Immunol. 2022;41(2):57-71. [Pubmed]
113. Muñoz-San Martín M, Gómez I, Quiroga-Varela A, González-Del Río M, Robles Cedeño R, Álvarez G, et al. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 9;10(1):e200069. [Pubmed]
114. Quintana E, Ortega FJ, Robles-Cedeño R, Villar ML, Buxó M, Mercader JM, et al. miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands. Mult Scler. 2017 Nov;23(13):1716-26. [Pubmed]
115. Muñoz-San Martín M, Torras S, Robles-Cedeño R, Buxó M, Gómez I, Matute-Blanch C, et al. Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics. 2020 Dec;12(23):2065-76. [Pubmed]
116. Johnson BN, Mutharasan R. Biosensor-based microRNA detection: techniques, design, performance, and challenges. Analyst. 2014 Apr 7;139(7):1576-88. [Pubmed]